Management of POEMS Syndrome

First-Line Treatment Based on Disease Extent

For localized disease with solitary or limited sclerotic bone lesions, radiation therapy is the definitive first-line treatment, achieving 97% 4-year overall survival and 52% 4-year failure-free survival, resulting in improvement in 50-70% of patients, according to the American College of Hematology 1, 2
For disseminated disease with diffuse sclerotic lesions or bone marrow involvement, systemic chemotherapy followed by autologous stem cell transplantation (ASCT) in eligible patients is the recommended approach, as suggested by the American Society of Clinical Oncology 1, 2

Melphalan-dexamethasone achieves 81% hematologic response and 100% improvement in neuropathy in prospective trials, making it a preferred regimen for disseminated disease, according to the National Comprehensive Cancer Network 1, 2
Lenalidomide-dexamethasone is preferred in patients with pre-existing neuropathy due to lower neurotoxicity risk compared to other agents, as recommended by the European Society for Medical Oncology 2

ASCT should be offered to eligible patients after induction chemotherapy, achieving 100% clinical improvement in transplant-eligible patients, according to the American Society of Clinical Oncology 1, 2

Thalidomide-based regimens should be avoided due to high neurotoxicity risk that can worsen pre-existing neuropathy, as warned by the American Academy of Neurology 1
Bortezomib-based combinations are not recommended as first-line due to induced neuropathy risk, despite high response rates, according to the National Comprehensive Cancer Network 1, 2

Neurologic improvement significantly lags behind hematologic response, with maximum neurologic response expected after 2-3 years of successful therapy, as noted by the American College of Hematology 1, 2
Optimal response on FDG-PET may lag by 6-12 months after treatment, according to the Society of Nuclear Medicine and Molecular Imaging 1

Serum VEGF levels should be monitored as a marker of disease activity and treatment response, as recommended by the American Society of Clinical Oncology 1, 2

Endocrinopathy management should address thyroid, adrenal, and gonadal dysfunction, according to the Endocrine Society 1
Thrombotic risk management should monitor for thrombocytosis and consider prophylaxis, as suggested by the American College of Chest Physicians 1
Pulmonary and cardiac assessment should include regular monitoring with pulmonary function tests and echocardiography, according to the American Thoracic Society 1

Patients who otherwise satisfy criteria for myeloma but are symptomatic due to POEMS syndrome should be managed differently, taking into consideration the manifestations of the associated condition, as recommended by the International Myeloma Society 3, 4